ImmunoPrecise Antibodies (IPA) News and press releases

Immunoprecise Antibodies Ltd. The Parent Company Of BioKey Announces European Patent Office To Grant Patent Application For Foundational HYFT Technology

27 Mar 23

Biotech, News, FDA, General

Company Received Official Notice from the European Patent Office (EPO) for the Decision to Grant its Patent Application on April 5th, 2023. The Patent was Initially Filed February 7th, 2020. Patent Application Covers

Stocks That Hit 52-Week Lows On Tuesday

21 Mar 23

Options

On Tuesday, 74 companies achieved new lows for the year.

Benchmark Maintains Speculative Buy on ImmunoPrecise Antibodies, Lowers Price Target to $7

21 Mar 23

News, Price Target, Analyst Ratings

Benchmark analyst Robert Wasserman maintains ImmunoPrecise Antibodies (NASDAQ:IPA) with a Speculative Buy and lowers the price target from $12 to $7.

Stocks That Hit 52-Week Lows On Monday

20 Mar 23

Options

On Monday, 198 companies hit new 52-week lows.

HC Wainwright & Co. Reiterates Buy on ImmunoPrecise Antibodies, Maintains $9 Price Target

17 Mar 23

News, Price Target, Reiteration, Analyst Ratings

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates ImmunoPrecise Antibodies (NASDAQ:IPA) with a Buy and maintains $9 price target.

Stocks That Hit 52-Week Lows On Thursday

16 Mar 23

Options

Thursday's session saw 337 companies set new 52-week lows.

Earnings Scheduled For March 16, 2023

16 Mar 23

Earnings

Companies Reporting Before The Bell • KVH Industries (NASDAQ:KVHI) is projected to report quarterly earnings at $0.03 per share on revenue of $34.29 million.

Earnings Outlook For ImmunoPrecise Antibodies

15 Mar 23

Earnings

ImmunoPrecise Antibodies' Subsidiary Talem Therapeutics Announced Multi-Target AI-Driven Antibody Discovery Collaboration With Libera Bio

15 Mar 23

News, Penny Stocks

Immunoprecise Antibodies Ltd.

European Patent Office to Grant BioKey's Patent Application for Foundational HYFT® Technology

27 Mar 23

Press Releases

Company Received Official Notice from the European Patent Office (EPO) for the Decision to Grant its Patent Application on April 5th, 2023. The Patent was Initially Filed February 7th, 2020. Patent Application Covers

ImmunoPrecise Presents Novel T-Cell Engaging Bispecific Antibodies Addressing a Unique Oncological Target, Tropomyosin Receptor Kinase B, Associated with Poor Prognosis and Survival Rates

23 Mar 23

Press Releases

Company to Present at the Upcoming 2023 Annual Meeting of the American Association for Cancer Research (AACR) ImmunoPrecise's Unique Proprietary Bispecific Antibodies Link Cells Expressing Tumor-Associated Antigen

IPA Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2023

16 Mar 23

Press Releases

IPA's Project revenue increased by 16.7% compared to the prior year, driven by the growth of the company's proprietary B cell Select® platform and protein manufacturing services. Talem Therapeutics has

ImmunoPrecise Antibodies' Subsidiary Talem Therapeutics Announces a Multi-Target AI-Driven Antibody Discovery Collaboration with Libera Bio

15 Mar 23

Press Releases

The program will leverage BioStrand's LENSai® Full Suite of Integrated Intelligence Technology® with Libera Bio's Multifunctional Polymeric Nanocapsules (MPN Technology®) The Alliance has Stipulated a

IPA to Report Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2023 on March 16, 2023

7 Mar 23

Press Releases

The Company to host an earnings conference call via webcast IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the "Company" or "IPA") (NASDAQ:IPA), an advanced biotherapeutic research and technology company, today announced that it